FGFR (fibroblast growth factor receptor) signalling plays critical roles in embryogensis, adult physiology, tissue repair and many pathologies. Of particular interest over recent years, it has been implicated in a wide range of cancers, and concerted efforts are underway to target different aspects of FGFR signalling networks. A major focus has been identifying the canonical downstream signalling pathways in cancer cells, and these are now relatively well understood. In the present review, we focus on two distinct but emerging hot topics in FGF biology: its role in stromal cross-talk during cancer progression and the potential roles of FGFR signalling in the nucleus. These neglected areas are proving to be of great interest clinically and are intimately linked, at least in pancreatic cancer. The importance of the stroma in cancer is well accepted, both as a conduit/barrier for treatment and as a target in its own right. Nuclear receptors are less acknowledged as targets, largely due to historical scepticism as to their existence or importance. However, increasing evidence from across the receptor tyrosine kinase field is now strong enough to make the study of nuclear growth factor receptors a major area of interest.
Skip Nav Destination
Article navigation
Review Article|
April 10 2014
The ins and outs of fibroblast growth factor receptor signalling
Stacey J. Coleman;
Stacey J. Coleman
*Centre for Tumour Biology, Barts Cancer Institute–a CRUK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, U.K.
Search for other works by this author on:
Charo Bruce;
Charo Bruce
*Centre for Tumour Biology, Barts Cancer Institute–a CRUK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, U.K.
Search for other works by this author on:
Athina-Myrto Chioni;
Athina-Myrto Chioni
*Centre for Tumour Biology, Barts Cancer Institute–a CRUK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, U.K.
Search for other works by this author on:
Hemant M. Kocher;
Hemant M. Kocher
*Centre for Tumour Biology, Barts Cancer Institute–a CRUK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, U.K.
†Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, U.K.
Search for other works by this author on:
Richard P. Grose
*Centre for Tumour Biology, Barts Cancer Institute–a CRUK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, U.K.
Correspondence: Dr Richard P. Grose (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
February 05 2014
Revision Received:
March 14 2014
Accepted:
March 14 2014
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2014 Biochemical Society
2014
Clin Sci (Lond) (2014) 127 (4): 217–231.
Article history
Received:
February 05 2014
Revision Received:
March 14 2014
Accepted:
March 14 2014
Citation
Stacey J. Coleman, Charo Bruce, Athina-Myrto Chioni, Hemant M. Kocher, Richard P. Grose; The ins and outs of fibroblast growth factor receptor signalling. Clin Sci (Lond) 1 July 2014; 127 (4): 217–231. doi: https://doi.org/10.1042/CS20140100
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.